{'52WeekChange': -0.013377905,
 'SandP52WeekChange': 0.0644362,
 'address1': '932 Southwood Boulevard',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.96,
 'askSize': 2200,
 'averageDailyVolume10Day': 1124600,
 'averageVolume': 1140728,
 'averageVolume10days': 1124600,
 'beta': 0.844257,
 'beta3Year': None,
 'bid': 2.95,
 'bidSize': 38500,
 'bookValue': 4.62,
 'category': None,
 'circulatingSupply': None,
 'city': 'Incline Village',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.06,
 'dayLow': 2.945,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.334,
 'enterpriseToRevenue': 2.72,
 'enterpriseValue': 231492944,
 'exDividendDate': 1464825600,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '775 832 8501',
 'fiftyDayAverage': 3.026,
 'fiftyTwoWeekHigh': 3.86,
 'fiftyTwoWeekLow': 2.06,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 104263899,
 'forwardEps': -0.06,
 'forwardPE': -49.166668,
 'fromCurrency': None,
 'fullTimeEmployees': 109,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.03554,
 'heldPercentInstitutions': 0.83915,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1002672000,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/pdl.com',
 'longBusinessSummary': 'PDL BioPharma, Inc. acquires, manages, and '
                        'commercializes commercial stage pharmaceutical assets '
                        'and late clinical stage pharmaceutical products in '
                        'North America, Europe, Asia, and internationally. The '
                        'company operates through Medical Devices, Strategic '
                        'Positions, Pharmaceutical, and Income Generating '
                        'Assets segments. The Medical Devices segment offers '
                        'LENSAR laser systems for anterior capsulotomy, lens '
                        'fragmentation, corneal and arcuate incisions to '
                        'ophthalmic ambulatory surgical centers, specialty '
                        'ophthalmic hospitals, and multi-specialty hospitals '
                        'through a direct sales force. The Strategic Positions '
                        'segment develops and commercializes various products '
                        "to address unmet needs in women's sexual and "
                        'reproductive health. The Pharmaceutical segment '
                        'manufactures, markets, and sells prescription '
                        'medicine products for the treatment of hypertension '
                        'to wholesalers under the Tekturna and Tekturna HCT '
                        'names in the United States, as well as under the '
                        'Rasilez and Rasilez HCT names internationally. The '
                        'Income Generating Assets segment consists of notes '
                        'and other long-term receivables; royalty rights and '
                        'hybrid notes/royalty receivables; equity investments '
                        'in healthcare companies; and royalties from issued '
                        'patents covering the humanization of antibodies, '
                        'including Avastin, Herceptin, Xolair, Perjeta, '
                        'Kadcyla, and Tysabri. The company was formerly known '
                        'as Protein Design Labs, Inc. and changed its name to '
                        'PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was '
                        'founded in 1986 and is headquartered in Incline '
                        'Village, Nevada.',
 'longName': 'PDL BioPharma, Inc.',
 'market': 'us_market',
 'marketCap': 336137760,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_321244',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -93501000,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.05,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.33,
 'phone': '775 832 8500',
 'previousClose': 3.07,
 'priceHint': 4,
 'priceToBook': 0.63852817,
 'priceToSalesTrailing12Months': 3.9500077,
 'profitMargins': -1.27869,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.06,
 'regularMarketDayLow': 2.945,
 'regularMarketOpen': 3.05,
 'regularMarketPreviousClose': 3.07,
 'regularMarketPrice': 3.05,
 'regularMarketVolume': 591904,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 113945000,
 'sharesPercentSharesOut': 0.09770001,
 'sharesShort': 11129651,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6199867,
 'shortName': 'PDL BioPharma, Inc.',
 'shortPercentOfFloat': 0.101,
 'shortRatio': 9.41,
 'startDate': None,
 'state': 'NV',
 'strikePrice': None,
 'symbol': 'PDLI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': 0,
 'trailingAnnualDividendYield': 0,
 'trailingEps': -0.929,
 'twoHundredDayAverage': 3.159928,
 'volume': 591904,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.pdl.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '89451'}